Payment overview · 2025
General Payments
$590.80
30 reported records · 16 companies
Healthcare provider profile · identity verified
Laura Ellen Boggs, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WATERTOWN, NY · NPI 1013105949
Verified facts
What the public records show
CMS Open Payments records show Laura Ellen Boggs, DO received $590.80 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $98.86 | 16.7% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $58.10 | 9.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.39 | 9.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.16 | 8.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.00 | 6.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.28 | 6.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $35.49 | 6.0% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $35.21 | 6.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.10 | 5.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $29.50 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.04 | 4.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.21 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.15 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.41 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.82 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.08 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $590.80 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $93.20 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $55.39 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.24 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $48.16 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $35.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.37 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 312 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
312 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
312 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 727 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 97 |
| Sertraline Hcl | Sertraline Hcl | 416 | 63 |
| Furosemide | Furosemide | 387 | 70 |
| Gabapentin | Gabapentin | 355 | 67 |
| Omeprazole | Omeprazole | 339 | 77 |
| Eliquis | Apixaban | 312 | 49 |
| Losartan Potassium | Losartan Potassium | 300 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 56 |
| Montelukast Sodium | Montelukast Sodium | 240 | 46 |
| Metformin Hcl | Metformin Hcl | 229 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 222 | 42 |
| Spironolactone | Spironolactone | 220 | 37 |
| Valsartan | Valsartan | 213 | 40 |
| Buspirone Hcl | Buspirone Hcl | 201 | 26 |
| Simvastatin | Simvastatin | 194 | 49 |
| Jardiance | Empagliflozin | 184 | 36 |
| Potassium Chloride | Potassium Chloride | 184 | 32 |
| Famotidine | Famotidine | 178 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 173 | 35 |
| Torsemide | Torsemide | 172 | 32 |
| Prednisone | Prednisone | 157 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 23 |
| Xarelto | Rivaroxaban | 134 | 16 |
| Lisinopril | Lisinopril | 131 | 34 |
| Divalproex Sodium | Divalproex Sodium | 122 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 115 | 25 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 114 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 108 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 27 |
| Allopurinol | Allopurinol | 103 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 23 |
| Farxiga | Dapagliflozin Propanediol | 101 | 24 |
| Carvedilol | Carvedilol | 100 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 19 |
| Mirtazapine | Mirtazapine | 84 | 15 |
| Irbesartan | Irbesartan | 80 | 22 |
| Sucralfate | Sucralfate | 80 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 13 |
| Atenolol | Atenolol | 76 | 19 |
| Trulicity | Dulaglutide | 73 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | 18 |
| Ozempic | Semaglutide | 68 | 17 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 59 | 11 |
| Olanzapine | Olanzapine | 55 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Finasteride | Finasteride | 53 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 31 |
| Baclofen | Baclofen | 52 | 12 |
| Chlorthalidone | Chlorthalidone | 50 | 11 |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 49 | 11 |
| Lansoprazole | Lansoprazole | 48 | suppressed |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 45 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Calcitriol | Calcitriol | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | 13 |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Fluconazole | Fluconazole | 41 | suppressed |
| Metolazone | Metolazone | 41 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 27 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 27 | suppressed |
| Acetic Acid | Acetic Acid | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Meloxicam | Meloxicam | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Klor-Con M10 | Potassium Chloride | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nystatin | Nystatin | 17 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 14 |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Cefdinir | Cefdinir | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $590.80 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAMZYOS, CREON, ELIQUIS, FARXIGA, GEMTESA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, REXULTI, REZDIFFRA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error